Primer: Paradigm Biopharmaceuticals (PAR AU) - Aug 2026
Paradigm is a late-stage, single-asset biopharmaceutical company whose value is almost entirely dependent on the clinical and commercial success...
112 Views
Australian Biotech Companies Amid Talk of Likely Interest Rate Cut
​RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...
474 Views
Paradigm Biopharmaceuticals (PAR AU): Fund Raising Amidst Pipeline Progress Raises Conviction
Paradigm Biopharmaceuticals has requested a trading halt pending an announcement in relation to a capital raising. Normal trading will resume on...
1k Views
Paradigm Biopharma - Termination of coverage
Edison Investment Research is terminating coverage on Atlantis Japan Growth Fund (AJG), Paradigm Biopharma (PAR), The European Smaller Companies...
494 Views
Paradigm Biopharma - Q1 results recap iPPS progress in OA & MPS
Paradigm announced Q1 results (for the quarter ending 30 September) and a A$30m capital raise to potentially extend its cash runway through to mid...
573 Views